Operable primary breast cancer with over expression/ amplification of HER2. MedDRA version: 20.0 Level: PT Classification code 10006187 Term: Breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Interventions
Trade Name: Tyverb
Product Name: Lapatinib
Product Code: GW572016
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Lapatinib ditosylate
CAS Number: 388082-78-8
Current Sponsor code: GW5720
Sponsors
Novartis Pharma Services AG
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age > or = 18 years; 2. Eastern Cooperative Oncology Group performance status or = T1c); 4. Known hormone receptor status (ER/PgR or ER alone); 5. Must have received at least four cycles of an approved anthracycline-based (neo-) adjuvant chemotherapy regimen; For design 1: Randomisation must be performed no longer than 12 weeks from day 1 of the last chemotherapy cycle. For design 2: Randomisation must be performed no longer than 6 weeks from day 1 of the last anthracycline-containing chemotherapy cycle. For design 1 & 2: Study treatment should start no more than 14 days after randomization; 6. Baseline LVEF > or = 50% after completion of all anthracycline-based (neo-) adjuvant chemotherapy and prior to the targeted therapy(ies); 7. Confirmed overexpression and/or gene amplification of ErbB2 (HER2) in the invasive component of the primary tumour, according to one of the following definitions: – 3+ overexpression by IHC (>30% of invasive tumour cells); – 2+ or 3+ (in 30% or less neoplastic cells) overexpression by IHC and positive in situ hybridisation (FISH/CISH) test; – ErbB2 (HER2) gene amplification by FISH/CISH; - Patients with a negative or equivocal overall result for overexpression and/or gene amplification are not eligible for participation in the trial; - Equivocal local results may be submitted for a final determination by the central laboratory. 8. Completion of all necessary baseline laboratory and radiological investigations; 9. Signed written informed consent prior to any study specific screening procedures. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 4000 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 4000
Exclusion criteria
Exclusion criteria: Patients meeting any of the following criteria are not eligible for this study: 1. History of any prior (ipsi- and/or contralateral) invasive breast carcinoma; 2. Past (less than 10 years) or current history of malignant neoplasms, unless curatively treated basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix. NOTE: Patients with a prior malignancy diagnosed greater than 10 years in the past who have been curatively treated with surgery ONLY, WITHOUT radiation therapy or systemic therapy (chemotherapy or endocrine) are eligible for the study. Patients with any prior diagnosis of breast cancer or melanoma, at any time, are excluded from this study; 3. Any clinically staged T4 tumour, including inflammatory breast cancer; 4. Bilateral tumours; 5. This exclusion criterion has been removed as of protocol amendment 1; 6. Maximum cumulative dose of doxorubicin >360mg/m2 or maximum cumulative dose of epirubicin >720mg/m2 or any prior anthracyclines unrelated to the present breast cancer; 7. Previous (neo-) adjuvant chemotherapy with peripheral stem cell or bone marrow stem cell support; 8. Any prior mediastinal irradiation except internal mammary node irradiation for the present breast cancer; 9. Patients with positive or suspicious internal mammary nodes identified by sentinel node technique which have not been irradiated or will not be irradiated, or patients with supraclavicular lymph node involvement; 10. Prior anti-ErbB2 (HER2) therapy for any reason, or other prior biologic or immunotherapy for breast cancer; 11. Concurrent anti-cancer treatment, except hormonal therapy or radiotherapy for the present breast cancer; 12. Concurrent anti-cancer treatment in another investigational trial with hormone therapy or immunotherapy unless approved by the Executive Committee; 13. Serious cardiac illness or medical conditions including but not confined to: – History of documented congestive heart failure (CHF) or systolic dysfunction (LVEF 180mm Hg or diastolic >100mm Hg); 14. Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness; 15. Any of the following abnormal laboratory tests immediately prior to randomisation: – serum total bilirubin; – alanine amino transferase (ALAT) or aspartate amino transferase (ASAT); – alkaline phosphatase (ALP); – serum creatinine; – total white blood cell count (WBC); – absolute neutrophil count; – platelets; 16. Unresolved or unstable serious toxicity from prior adjuvant chemotherapy or radiotherapy; 17. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, or persons unable to swallow oral medication. Patients with ulcerative colitis are also excluded; 18. Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test - urine or serum - within 7 days prior to randomisation); 19. Women of childbearing potential including women whose last menstrual period was <1 year ago (unless surgically st
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare disease-free survival (DFS) in patients with HER2 overexpressing and/or amplified breast cancer randomised to trastuzumab for one year versus lapatinib for one year versus weekly trastuzumab (12 or 18 weeks, according to assigned design) followed by a six-week washout period followed by lapatinib (28 or 34 weeks, according to assigned design) versus trastuzumab in combination with lapatinib for one year.;Secondary Objective: The secondary objectives of the study are to evaluate and compare the following criteria between treatment arms: Overall survival (OS), time to recurrence (TTR), time to distant recurrence (TTDR), cumulative incidence of brain metastases as the first site of breast cancer recurrance. In addition the safety and tolerability of all four treatment groups will be evaluated. Exploratory Translational Research Objective: To evaluate the quantative HER2 protein and/or HER2 domain levels (e.g. presence or absence of p95 HER2 domain or ratio of intracellular and extracellular HER2 expression levels) and determine the relationship with response to HER2 targeted agents and clinical outcome.;Primary end point(s): The primary endpoint for analysis is disease-free survival (DFS) which will be defined as the time from randomisation until the first occurrence of: 1. Breast cancer recurrence at any site; 2. A second primary cancer (invasive contralateral breast or non-breast malignancy); 3. Death from any cause as first event.;Timepoint(s) of evaluation of this end point: Not applicable | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable | — |
Countries
Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Slovakia, Slovenia, Spain, United Kingdom
Contacts
Public ContactClinical Trial Information Desk
Novartis Pharma Services AG
Outcome results
None listed